Back to Search
RICHARD RUDICK, MD
MD
Neurology Physician
NPI: 1679500540Individual
Specialties, Licenses & Credentials
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
35054570(OH)
Research & Publications (20)
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS.
PMID 19100997·J Neurol Sci·2009
8-other
Assessing disability progression with the Multiple Sclerosis Functional Composite.
PMID 19667023·Mult Scler·2009
8-other
Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
PMID 19506220·Neurology·2009
3-trial
Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.
PMID 19446274·Lancet Neurol·2009
6-review
Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment.
PMID 18788835·CNS Drugs·2008
6-review
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.
PMID 18774923·Expert Opin Biol Ther·2008
6-review
Health-related quality of life in multiple sclerosis: effects of natalizumab.
PMID 17696126·Ann Neurol·2007
2-rct
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
PMID 16510745·N Engl J Med·2006
3-trial
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study.
PMID 16786526·Ann Neurol·2006
8-other
Disease modification in multiple sclerosis: issues with relevance to clinical trial designs in Alzheimer's disease.
PMID 19595872·Alzheimers Dement·2006
8-other
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
PMID 16323317·Mult Scler·2005
3-trial
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
PMID 15853576·Expert Rev Neurother·2004
6-review
Defining interferon beta response status in multiple sclerosis patients.
PMID 15389896·Ann Neurol·2004
3-trial
Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
PMID 15228760·J Neuroimaging·2004
6-review
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance.
PMID 14610110·Neurology·2003
6-review
Mechanisms of disability progression in primary progressive multiple sclerosis: are they different from secondary progressive multiple sclerosis?
PMID 12708817·Mult Scler·2003
6-review
The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.
PMID 12356200·Mult Scler·2002
6-review
Contemporary immunomodulatory therapy for multiple sclerosis.
PMID 11756861·J Neuroophthalmol·2001
6-review
Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications.
PMID 11756860·J Neuroophthalmol·2001
6-review
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
PMID 11376182·Neurology·2001
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9500 EUCLID AVE
CLEVELAND, OH 44195 - Phone
- (800) 223-2273
Quick Facts
- NPI
- 1679500540
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile